NCT06663748View on ClinicalTrials.gov

ARX788 in HER2-positive Metastatic Breast Cancer Patients

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

November 20, 2024

Primary Completion Date

November 20, 2025

Study Completion Date

November 20, 2029

Conditions
HER2-positive, Metastatic Breast Cancer
Interventions
DRUG

ARX788

2.2 mg/kg IV infusion on Day 1 of each 42-day treatment cycle.

All Listed Sponsors
lead

Henan Cancer Hospital

OTHER_GOV

NCT06663748 - ARX788 in HER2-positive Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter